Showing results (21-30 of 127) with videos related to
Sort By:
Pageof 13
Frontiers in Neurology|May 15, 2026
Case Report: B-cell-targeted therapy with ofatumumab achieves remission in refractory panuveitis and coexisting multiple sclerosisAgni M Konitsioti, Jeany Q Lammert, Sabine Vay, et al.Journal of Neurology|March 22, 2024
Persons with multiple sclerosis older than 55 years: an analysis from the German MS registryYasemin Goereci, David Ellenberger, Paulus Rommer, et al.Neurological Research and Practice|October 4, 2021
Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccinationYasemin Goereci, Nina N Kleineberg, Marie Madlener, et al.Journal of Neurology, Neurosurgery, and Psychiatry|August 14, 2018
Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohortMartijn T Wijburg, Clemens Warnke, Frederik Barkhof, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 24, 2020
Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complicationsMartijn T Wijburg, Clemens Warnke, Christopher McGuigan, et al.The Journal of Cell Biology|March 30, 2005
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stabilityFrank Henkler, Eva Behrle, Kevin M Dennehy, et al.Clinical Immunology (Orlando, Fla.)|July 8, 2011
Cladribine as a therapeutic option in multiple sclerosisClemens Warnke, Verena I Leussink, Norbert Goebels, et al.Current Opinion in Neurology|April 16, 2019
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosisFinja Schweitzer, Sarah Laurent, Gereon R Fink, et al.Journal of Neurology|July 22, 2020
A systematic review of neurological symptoms and complications of COVID-19Xiangliang Chen, Sarah Laurent, Oezguer A Onur, et al.CNS Drugs|October 17, 2021
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in NeurologyFabian Szepanowski, Clemens Warnke, Gerd Meyer Zu Hörste, et al.Pageof 13